Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer.

Award Number: R41CA306696
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/18/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer. - Project Summary Tezcat Biosciences is developing novel receptor-independent intracellular drug delivery technology with a unique mechanism of action to treat the most recalcitrant cancers, such as mutant RAS pancreatic cancer. Pancreatic ductal adenocarcinoma cancer (PDAC) is associated with a dismal 5-year survival rate and pancreatic cancer patients today have virtually the same therapeutic options available to patients decades ago. This dearth of effective treatments is due in part to the notorious difficulty in targeting the genetic driver of PDAC, oncogenic RAS, as well as features of the PDAC tumor microenvironment itself which obstruct drug delivery. We have observed that mutant RAS PDAC cells display high levels of macropinocytosis, a nutrient scavenging process that facilitates the bulk engulfment of extracellular fluid and its solutes. Our drug candidate, TZT-102, utilizes our proprietary macropinocytosis-selective monobody that carries an FDA-approved cytotoxic payload (MMAE). Results from previous projects demonstrate that TZT-102 has robust anti-tumor activity in mutant RAS PDAC xenograft and orthotopic models without displaying systemic toxicity. As cancer cells, especially mutant RAS PDAC, exhibit high rates of acquired drug resistance, we are developing a novel dual-payload approach that combines the anti-microtubule payload (MMAE) with a DNA-damaging radioisotope. This proposal will utilize an imaging radioisotope (67Ga) to first provide proof-of-concept for 1) feasibility of synthesis and radiolabeling of the parent compound (TZT-102), and 2) biodistribution and tumor imaging data to confirm that the dual-payload conjugate maintains tumor-targeting capabilities. Tezcat has entered into a license agreement with NYU Langone Health for exclusive, worldwide rights to the technology being developed. Successful completion of the aims will support a Phase II SBIR application for testing of a dual-payload carrying a therapeutic radioisotope (177Lu).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $399,855 )
2026	2026	TEZCAT BIOSCIENCES, INC.	470 JAMES STREET	NEW HAVEN	CT	06513	SOUTH CENTRAL CT	USA	Cancer Treatment Research	000	1	8/18/2026	NEW	$399,855
														Subtotal = $399,855

Grand Total All Awards = $399,855

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer.

Award Number: R41CA306696

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/18/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer